Table 1. Summary of the studies included in the meta-analysis.
| Author | Year | Study design | Number (3DCRT/IMTR) | PTV | total dose/fraction dose (Gy) (3DCRT VS IMRT) | Margin (mm) | Method for dose prescript-ion | Image guidance | ADT%(3DCRT/IMRT) & p value | Tumor stage I/II (III/IV) | Median follow-up (m)(3DCRT/IMRT) | score criteria |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| post-operative RT (n = 2) | ||||||||||||
| Alongi F[36] | 2009 | Retro. | 172(81/91) | Prostatic bed, Pelvic nodes | 72.1/1.8 VS 72.5/1.8 | 8 | Isodose level | NO | 61/56n.s. | NR/NR | 3/3 | RTOG toxicity scale |
| Goenka A[37] | 2011 | Retro. | 285 (109/176) | NR | 66-72/NR VS 66-72/NR | NR | NR | NO | 100/100n.s. | NR/NR | 97/53 | RTOG toxicity scale,CTCAE version 3.0 |
| Primary RT (n = 21) | ||||||||||||
| Ashman JB[38] | 2005 | Retro. | 27 (14/13) | Prostatic bed, Pelvic nodes, seminal vesicles | 75.6/1.8 VS81/1.8 | 10 | Isocenter | NO | 100/100n.s. | 12/15 | 30/30 | RTOG toxicity scale |
| Cho JH[39] | 2008 | Retro. | 50 (35/15) | Prostatic bed | 70.2/1.8 VS70/2.5 | NR | Isocenter | NO | 44/44n.s. | 26/24 | 3/3 | RTOG toxicity scale |
| Dolezel M[40]* | 2010 | Pro. | 232 (94/138) | Prostatic bed, Pelvic nodes, seminal vesicles | 74/2 VS78/2 | 10 | Isocenter | NO | 94.7/55 | 76/156 | 68.4/37.2 | RTOG toxicity scale |
| Dolezel M[41]* | 2015 | Pro. | 533 (320/233) | Prostatic bed, seminal vesicles | 70-74/2 VS78-82/2 | 10 | Isocenter | NO | 40.3/62.3 | 332/221 | 104/60 | RTOG toxicity scale, ASTROPhoenix definition |
| Forsythe K [42] | 2011 | Retro. | 812 (521/291) | Prostatic bed,seminal vesicles | NR | 10–12 | Isocenter | Partly | 87.9/75.9p <0.01 | NR/NR | 74.4/33.6 | RTOG toxicity scale |
| Jani AB[43] | 2007 | Pro. | 481(373/108) | Prostatic bed,seminal vesicles | 68.5/1.8–2 VS75/1.8–2 | 10 | NR | NO | 53/51 | 413/68 | NR/NR | RTOG toxicity scale |
| Kim H[44] | 2014 | Retro. | 86 (56/30) | Prostatic bed, Pelvic nodes,seminal vesicles | 70/1.8 VS70/2.5 | 5 | Isocenter | NO | 56.7/53.6n.s. | 43/43 | 78.6/73.4 | RTOG toxicity scale |
| Kupelian PA[45]* | 2002 | Retro. | 282 (116/166) | Prostatic bed, Pelvic nodes, seminal vesicles | 78/2 VS70/2.5 | 8–15 | Isodose level | NO | 72/60p = 0.049 | 263/19 | 25/25 | RTOG toxicity scale, ASTROPhoenix definition |
| Odrazka K[46]* | 2010 | Retro. | 340(228/112) | Prostatic bed, seminal vesicles | 70/2 VS78/2 | 10–15 | Isocenter | NO | 19.7/54.5 | NR/NR | 70.8/36 | RTOG toxicity scale |
| Ratnayake G[47] | 2013 | Pro. | 103 (52/51) | Prostatic bed, Pelvic nodes, seminal vesicles | 74 or 78/2 VS78/2 | 7–10 | Isodose level | YES | 31/59p = 0.06 | 83/19 | 48/38 | RTOG toxicity scale |
| Sharma NK[48] | 2007 | Retro. | 293(170/123) | Prostatic bed, Pelvic nodes, seminal vesicles | 76/2 VS76/1.8 | 10 VS 3–5 | Isodose level | NO | 100/100n.s | 223/70 | 86/40 | RTOG toxicity scale |
| Someya M[49] | 2015 | Retro. | 129 (55/74) | Prostatic bed, seminal vesicles | 70/2 VS 78/2 | 10 VS 8 | Isocenter | NO | 83.6/70.3 | 104/25 | 85/38 | RTOG toxicity scale |
| Sveistrup J[50] | 2014 | Retro. | 503(115/388) | Prostatic bed, seminal vesicles | 76/2 VS 78/2 | 10 VS 5–7 | NR | IG-IMRT | 88/95p = 0.019 | 128/373 | 98.4/42 | CTCAE version 4.0,ASTROPhoenix definition |
| Troeller A[51]* | 2015 | Pro. | 1115(457/658) | Prostatic bed, seminal vesicles | 75.6/1.8 VS 75.6/1.8 | 10 | Isodose level | YES | 23.2/19.9 p = 0.21 | NR/NR | 106.8/55.2 | CTCAE version 3.0 |
| Vora SA[52] | 2007 | Retro. | 416(271/145) | Prostatic bed, seminal vesicles | 68.4/NR VS75.6/NR | 10–20 VS 6–10 | NR | NO | 17.6/30.3 | 386/30 | 60/48 | RTOG toxicity scale, ASTROPhoenix definition |
| Wong WW[33] | 2009 | Retro. | 584(270/314) | Prostatic bed, seminal vesicles | 68.4/1.8–2 VS 75.6/NR | 10–20 VS 6–10 | NR | NO | 17/36 | 543/41 | 120/120 | RTOG toxicity scale, ASTROPhoenix definition |
| Zelefsky MJ[53] | 2000 | Retro. | 232(61/171) | Prostatic bed, seminal vesicles | 81/1.8VS 81/1.8 | 10 | Isocenter | NO | 34/53 | 194/38 | 39/12 | RTOG toxicity scale |
| Zelefsky MJ[54] | 2007 | Retro. | 1571(830/741) | NR | 66-81/1.8 VS 81/NR | NR | Isocenter | NO | 43 | NR/NR | 120/78 | CTCAE version 3.0 |
| Shu HK[55] | 2001 | Retro. | 44 (26/18) | Prostatic bed, seminal vesicles | NR | 7.5–10 | Isodose level | NO | 79.5 | 33/11 | 30.1/18.7 | RTOG toxicity scale |
| Wortel RC[56]* | 2015 | RCT | 475(215/260) | Prostatic bed, seminal vesicles | 78/2 VS 78/2 | 10 VS 5–8 | NR | IG-IMRT | 19.5/66.9 | 262/213 | 3/3 | RTOG toxicity scale |
| Matzinger O[57] | 2009 | RCT | 791(652/139) | NR | 70-78/2VS 74-78/2 | NR | Isodose | NO | 50 | 791/0 | NR/NR | CTCAE version 2.0 |
Abbreviations: PTV = Planning target volume;retro = Retrospective study; pro = prospective study; RCT = Randomized controlled trial; ADT = Androgen deprivation therapy; NR = Not reported.
*represent studies which contain patients who underwent surgery.